Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Key Highlights
- ➤EIK1003 monotherapy ORR reached 14.3% overall and 31.3% in PARP-naïve participants
- ➤EIK1003 plus paclitaxel delivered 26.4% ORR, including one confirmed complete response
- ➤EIK1004 showed 17.6% Grade 3+ TEAEs, with anemia and neutropenia each at 1.5%
- ➤EIK1005 monotherapy produced stable disease in 6 of 8 efficacy-evaluable participants
- ➤EIK1005 plus pembrolizumab produced a partial response in the first treated participant
Expert Statements
Roy Baynes, Chief Medical Officer of Eikon Therapeutics
“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs,”
Roy Baynes, Chief Medical Officer of Eikon Therapeutics
“The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor.”
Roy Baynes, Chief Medical Officer of Eikon Therapeutics
“The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”
* Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies within the PARP inhibitor landscape * Initial results from ongoing Phase 1/2 study of highly selective CNS-penetrant PARP1 inhibitor EIK1004 demonstrate a generally well-tolerated safety profile across multiple dose levels, with minimal Grade 3 or higher hematologic toxicities as of the safety data cutoff * Preliminary data for Werner (WRN) helicase inhibitor EIK1005 support continued development as monotherapy and in combination with pembrolizumab, with pharmacokinetic (PK) profile supporting weekly administration * Additional data from PARP1-selective and WRN helicase programs expected in 2027 MILLBRAE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
Get started
Create a free account to read the full story.